Not-so-minimal for minimally invasive surgery

Sub?macular hemorrhage poses a potential threat to vision if left untreated. The preferred surgical technique to clear sub?macular hemorrhage includes vitrectomy followed by retinotomy using a 41G needle with subsequent injection of recombinant tissue plasminogen activator (r?tPA) followed by air/SF6 injection into the sub?retinal space. A malleable nature, increased resistance, and the cost of the 41G needle limit its use. We evaluated the safety and efficacy of a 26G needle for retinotomy as a supplement for the 41G needle in a series of six subjects with sub?macular hemorrhage. A slight modification in the procedure was done by injecting air into the sub?retinal space prior to the r?tPA injection. We found that our technique of using the 26G needle for retinotomy is safe and effective due to its stable nature and self?sealing properties. An air injection prior to r?tPA allows for increased bioavailability of the drug by preventing efflux due to its tamponading effect.

Uso y Administración del rtPA (activador tisular del plasminógeno): cuidados de enfermería / Use and Administration of rtPA (tissue plasminogen activator): nursing care

Si bien el uso rtPA está indicado para diversas patologías como el tratamiento trombolítico en los infartos agudos de miocardio, el tromboembolismo pulmonar agudo con inestabilidad hemodinamica y el tratamiento trombolítico del accidente cerebrovascular isquémico agudo conforme a la disposición DI­2018-495-APN-ANMAT#MSYDS el uso del mismo en Argentina y conforme a consenso (consenso sobre accidente cerebrovascular isquémico agudo). La administración oportuna del rtPA, a pacientes apropiadamente seleccionados constituye el principal tratamiento de forma temprana en el ACV (1-8). Por lo que el rol que cumple enfermería es fundamental en la valoración de riesgos previa a la administración, preparación, administración del fármaco y valoración continua post administración del mismo[AU]

Although the use of rtPA is indicated for various pathologies such as thrombolytic treatment in acute myocardial infarctions, acute pulmonary thromboembolism with hemodynamic instability, and thrombolytic treatment of acute ischemic stroke according to the DI-2018-495-APN-ANMAT provision. #MSYDS the use of thesame in Argentina and accordingtoconsensus (consensus on accident cerebrovascular ischemico acute). Timely administration of rtPAto appropriately selected patients constitutes the main treat mentearly in stroke (1,8). Therefore, the role play edby nursingis fundamental in the risk ass essment prior to the administration, preparation, administration of the drug, and continuous post-administration assessment[AU]

Embora o uso de rtPA seja indicado para várias patologias, como tratamento trombolítico em infartos agudos do miocárdio, tromboembolismo pulmonar agudo com instabilidade hemodinâmica e tratamento trombolítico de acidente vascular cerebral isquêmico agudo de acordo com a disposição DI- 2018-495-APN-ANMAT. #MSYDS a uso do mesmona Argentina e de acordocom o consenso (consensus on accident cerebrovascular ischemico agute). A administração oportuna de rtPA a pacientes adequadamente selecionados constitui o principal tratamento no início do AVC (1,8). Por tanto, o papel da enfermagem é fundamental na avaliação do risco antes da administração, preparo, administração do medicamento e avaliação pós-administração contínua[AU]

Tratamiento y manejo fibrinolítico en síndrome de Nicolau: Caso clínico / Fibrinolytic treatment and management in Nicolau syndrome: Clinical case

RESUMEN Introducción: El síndrome de Nicolau (SN), conocido como embolia cutis medicamentosa o dermatitis livedoide es un acontecimiento adverso debido a la administración de inyecciones intramusculares, intraarteriales, subcutánea e incluso intraarticulares asociado a diversos fármacos1. Se desconoce toda la patogenia de este síndrome, pero se ha asociado a lesión vascular, trombosis arterial, espasmo reflejo de las arterias, oclusión vascular por microembolia e inflamación. Caso clínico: Paciente masculino de 32 años de edad, luego de inyección intramuscular de penicilina benzatínica presenta dolor intenso en área de inyección que se acompaña de lesiones eritematosas a nivel de abdomen, escroto y miembro inferior derecho además de presentar dolor, pareste-sia, palidez moteado eritematoso (livedo) y disminución de pulsos en dicha extremidad por lo que se diagnostica isquemia aguda (IA) que requirió tratamien-to fibrinolitico, entre otros fármacos. Conclusión: El síndrome de Nicolau es una condición iatrogénica que puede ser producida por inyección de múltiples medicamentos, puede presentar diferentes síntomas y signos como lesión neurológica, necrosis en área de irrigación de vasos afectados e incluso isquemia aguda. En este caso el manejo con rt-PA fue efectivo en tratar la isquemia. El conocimiento de este síndrome y sus complicaciones facilitaría su manejo2.Palabras claves: Síndrome Nicolau, bencilpenicilina, anticoagulante, rt-PA

ABSTRACT Introduction: Nicolau syndrome (NS), known as cutaneous embolism or livedoid dermatitis, is an adverse event due to the administration of intramuscular, intraarterial, subcutaneous and intraarticular injections associated with various drugs1. The entire pathogenesis of this syndrome is unknown, but it has been associated with vascular injury, arterial thrombosis, reflex spasm of the arteries, vascular occlusion due to microemboli, and inflammation. Clinical case: 32-year-old male. After an intramuscular injection of benzathine penicillin, the patient presented severe pain in the injection area accompanied by erythem-atous lesions at the level of the abdomen, scrotum, and right lower limb. In addition to that, the patient presented pain, paresthesia, and mottled paleness erythema (livedo). Moreover, the patient had a decreased pulse in the right limb, acute ischemia was diagnosed and required fibrinolitic treatment, among other drugs. Conclusion: Nicolau Syndrome, is an iatrogenic condition that is produced by injection of multiple drugs. It can produce different symptoms and signs from neurological injury, necrosis in the irrigation area of affected vessels and acute ischemia. rt-PA management in this case was effective in treating ischemia. It is essential to know about this syndrome and its complications. This would facilitate its management2.Keywords: Nicolau syndrome, benzylpenicillin, anticoagulant, rt-PA.

A case of acute cerebral infarction with a favorable prognosis after rt-PA administration by a general physician with telestroke support / Journal of Rural Medicine

Objective: Herein, we report a patient with acute cerebral infarction with a favorable prognosis after being managed by a general physician with support from the telestroke program.Patient and Methods: An 85-year-old man was transferred to a regional hospital due to sudden onset of dysarthria and left hemiparesis. As no neurosurgeons or neurologists were available in that hospital or area, the patient was examined by a general physician who diagnosed him with cardioembolic stroke on the left middle cerebral artery territory. The physician consulted a stroke specialist using the telestroke system; with the support from the telestroke program, the physician administered thrombolytic therapy 4 hours and 10 minutes after the onset of symptoms.Results: The patient’s National Institutes of Health Stroke Scale score improved from 9 to 3 and he was subsequently transferred to the stroke center. However, the occluded left middle cerebral artery had already re-canalized. His hemiparesis completely improved one week after the onset.Conclusion: A telemedicine system for general physicians is indispensable in areas without accessible stroke specialists as it provides access to a standard of care for hyper-acute stroke patient assessment and management, and helps improve neuroprognosis.

Consenso colombiano de fibrinólisis selectiva con catéter en enfermedad vascular tromboembólica / Colombian consensus on selective thrombolysis with catheter in thromboembolic vascular disease

Resumen En los pacientes con trombosis arterial o venosa, in situ o por embolia, el uso de fibrinolíticos (como el rtPA) administrados directamente en el trombo a través de un catéter selectivo en el sitio de la oclusión, permite una resolución más rápida de la oclusión trombótica o embólica con menos dosis total del agente fibrinolítico y por ende con menos complicaciones hemorrágicas que con el uso sistémico. Las indicaciones en las cuales se puede considerar la fibrinólisis selectiva con catéter son básicamente la isquemia aguda de una extremidad por oclusión arterial, la tromboembolia pulmonar, la trombosis venosa profunda iliofemoral (proximal), la trombosis venosa profunda proximal axilo-subclavia, la trombosis de los accesos venosos para diálisis y en los pacientes pediátricos en los casos de trombosis o embolia arterial con extremidad isquémica y en casos seleccionados de trombosis venosa profunda proximal de extremidades. En este consenso describirá cada una de las indicaciones a través de un protocolo para el manejo con rtPA en cada situación, cómo monitorizar su uso y cómo tartar las complicaciones hemorrágicas.

Abstract In patients with arterial or venous thrombosis, in situ or due to an embolism, the use of fibrinolytics (such as recombinant tissue-type plasminogen activator, rtPA) administered directly into the clot through a selective catheter into the occlusion site. This can lead to a more rapid resolution of the thrombotic or embolic occlusion with a lower dose of the fibrinolytic agent, and therefore with less problems with haemorrhages than with systemic use. The situations in which selective fibrinolysis with a catheter can be considered are mainly, acute ischaemia of a limb due to a blocked artery, pulmonary thromboembolism, proximal ileo-femoral deep venous thrombosis, proximal axillo-subclavian deep venous thrombosis, and in the thrombosis of the venous access for dialysis It is also indicated in paediatric patients in cases of arterial thrombosis or embolisms with an ischaemic limb, and in selective cases of proximal deep venous thrombosis of the limbs. In this consensus, a description will be given of each one of the indications, with a protocol for the management with rtPA in each one of them, as well as monitoring its use and the management of haemorrhage complications.

Predictors of functional outcome in patients with stroke thrombolysis in a tertiary hospital in Malaysia

INTRODUCTION@#Intravenous (IV) thrombolysis with alteplase (rt-PA) is effective in ischaemic stroke. The primary objective was to evaluate predictors of functional outcome in acute ischaemic stroke (AIS) patients treated with IV rt-PA. The secondary objective was to assess the outcome with the modified Rankin scale (mRS). We also examined the predictive value of the Totaled Health Risks in Vascular Events (THRIVE) score.@*METHODS@#AIS patients treated with IV rt-PA from February 2012 to August 2016 were recruited. Demographic data, National Institutes of Health Stroke Scale (NIHSS) scores, timing and neuroradiological findings were recorded. Patients received a dose of 0.9 mg/kg IV rt-PA within 4.5 hours of symptom onset. mRS score was evaluated at discharge and three months, and good and poor clinical outcomes were defined as scores of 0-2 and 3-6, respectively. Baseline THRIVE scores were assessed.@*RESULTS@#36 patients received IV rt-PA. 20 (55.6%) patients had an mRS score of 0-2 at three months. Based on THRIVE score, 86.1% had a good or moderately good prognosis. On univariate analysis, poor outcome was associated with NIHSS score before rt-PA (p = 0.03), THRIVE score (p = 0.02), stroke subtype (p = 0.049) and diabetes mellitus (DM; p = 0.06). Multiple logistic regression showed that outcome was significantly associated with NIHSS score before rt-PA (p = 0.032) and DM (p = 0.010).@*CONCLUSION@#Our newly developed Malaysian IV rt-PA service is safe, with similar outcomes to the published literature. Functional outcome after thrombolysis was associated with baseline NIHSS score and DM.

Frequency of stroke patients qualified for recombinant tissue plasminogen activator (r-TPA) injection and limitations in Zahedan 2016

Background: Stroke is one of the common causes of mortality and disability. By introducing r-TPA into the global drug market and its effect on the patients’ prognosis, using this drug is recommended in all patients with ischemic stroke who visited less than 4.5 hours after stroke and do not have contraindications. The aim of this study was to investigate the frequency of stroke patients qualified for recombinant tissue plasminogen activator (r-TPA) and its limtations.Methods: In this descriptive cross-sectional study, 244 patients examined with stroke admitted to the Neurology Department of Zahedan city hospital in 2016. Information form were completed with demographic data, transmission method, referral time, CT scan preparation time, and the response of the patients' trials, and finally the data were inserted in SPSS.16 software and analysed by statistical methods.Results: Out of all patients with ischemic stroke, 28 (11.5%) patients had contraindication to receive drug. Of 216 remain patients, 201 patients (93.1%) had no possibility to receive r-TPA due to the loss of golden time and only 15 patients (6.9%) had possibility to receive drug because of visited 4.5 hours before the beginning of symptoms. Of them, 3 (20%) patients due to delay in CT scan and test results, had no possibility to receive r-TPA. In summary, of all patients with inclusion criteria, only 12 (5.5%) patients could use the r-TPA in this study.Conclusions: The most important barrier to using r-TPA has been the loss of golden time and training to raise awareness of the society can lead to early referral from the onset of stroke symptoms.

Clinical profile of patients with acute ischemic stroke receiving intravenous thrombolysis (rtPA-alteplase)

Background: Stroke patients are at highest risk death in the first few weeks after the event, and between 20-50% die within first month depending on type, severity, age, co-morbidities and effectiveness of treatment of complications. Objective of this study was to clinical profile of patients with acute ischemic stroke receiving intravenous thrombolysis (rtPA-alteplase).Methods: Prospective Observational study of 26 cases of acute ischemic stroke receiving IV thrombolysis using rtPA-alteplase at Kovai Medical Centre Hospital, Coimbatore over a period of 1 year 9 months.Results: 21 cases had NIHSS score of range 10 to 22. The mean NIHSS score at admission is 13.5. 15 subjects (57.7%) had achieved primary outcome in this study. MRS Score of 0 to 2 is considered as favorable outcome. In this study 20 subjects (76.92 %) had favorable outcome at the end of 3 months.Conclusions: Majority of the patients receiving rtPA-alteplase had favorable outcome

Thrombolysis for stroke in a tertiary care center from Hyderabad

Background: Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) within 4.5 hours of symptom onset is currently approved for treatment of acute ischemic stroke. It improves the rate of favourable outcomes despite the risk of hemorrhagic transformation. Aim: To study the outcomes of IV thrombolysis. Materials and methods: All patients who came to the emergency with in window period with signs and symptoms suggestive of acute ischmeic stoke were included in the study. CT brain plain was done to rule out ICH. Base line glucose and BP was recorded. NIHSS was calculated. Patients whose score was between 5-25 were given IV thrombolysis with rTPA or tenecteplase. Drug was given according to availability and it was free of cost Results: Total of 41 patients was given thrombolysis. 28 were given alteplase and 13 were given tenecteplase. Improvement in NIHSS was 3.34 points at the time of discharge. Almost 40% improved significantly improved in follow up mRS scores Conclusion: Our study concluded that thrombolysis for ischemic stroke provides early functional ability and decreased morbidity without any significant risk of bleeding

Acute pancreatitis is a very rare comorbidity of acute ischemic stroke / Journal of Rural Medicine

Background: Although acute pancreatitis is listed among the exclusion criteria for the administration of recombinant tissue plasminogen activator according to the Japanese Guideline for the Management of Stroke, the co-occurrence of acute pancreatitis and acute ischemic stroke has not been investigated. The present study aimed to assess the incidence rate of acute pancreatitis in patients with acute ischemic stroke.Methods: This study consecutively enrolled all patients with ischemic stroke admitted to the Department of Neurology, JA Toride Medical Center between April 2014 and March 2016. Diagnosis of acute pancreatitis was made according to the revised Atlanta Classification of Acute Pancreatitis. We retrospectively analyzed serum amylase activity and the frequency of acute pancreatitis as a comorbidity of ischemic stroke.Results: A total of 411 ischemic stroke patients were included. Serum amylase activity was measured for 364 patients, 27 of whom presented with amylase activity exceeding the upper limit of normal. In two patients with serum amylase activity greater than three times-fold the upper limit of normal, computed tomography or transabdominal ultrasonography showed no characteristic findings of acute pancreatitis. No patient in the cohort met the diagnostic criteria for acute pancreatitis.Conclusions: Acute pancreatitis is a very rare comorbidity of acute ischemic stroke.

Interventional treatment by catheter-directed thrombolysis for subacute iliofemoral venous thrombosis: comparison of instant efficacy between recombinant human tissue plasminogen activator and urokinase / 中华放射学杂志

Objective To compare the safety and clinical efficacy of recombinant human tissue plasminogen activator (rt-PA) and urokinase(UK)in catheter-directed thrombolysis(CDT)for the treatment of subacute iliofemoral deep venous thrombosis(DVT). Methods From June 2013 to June 2017, a total of 116 subacute DVT patients underwent consistent CDT with either rt-PA or urokinase, or simple anticoagulation treatment in this study.The patients were divided into three groups for comparison:rt-PA-CDT group(n=43), UK-CDT group(n=39)and anticoagulation group(n=34). The baseline data, thrombolysis duration, rt-PA or UK dosages, thrombolytic rate and clinical efficacy rate were compared among the three groups. Independent t-test(accorded to normal distribution)was used to analyze the thrombolysis duration.The quantitative data were analyzed with analysis of varianc and the qualitative data were compared by the chi-square test. Results There was no significant difference in general clinical features among the three groups(P>0.05). The thrombolysis duration, total dosages and thrombolytic rate (≥50)were(5.8±1.3)d,(49.7±16.1)mg,86.0% for rt-PA-CDT group,and(6.3±1.5)d,(440±99)×104 U, 66.7% for UK-CDT group.The difference of thrombolysis duration was not statistically significant between the rt-PA-CDT group and UK-CDT group(t=-1.868, P>0.05). The thrombolysis rate of rt-PA-CDT group was significantly higher than that of UK-CDT group(χ2=4.315, P<0.05). The time of obtaining grade Ⅲthrombosis rate was shorter for rt-PA-CDT group(4.7±0.9)d compared with UK-CDT group(6.0±1.2 d) (t=-2.343,P<0.05).The clinical efficacy rates of the rt-PA-CDT group[88.4%(38/43)]and UK-CDT group [76.9%(30/39)]were significantly higher than that of anticoagulation group[26.5%(9/34)](P<0.05).There was no statistical difference between the rt-PA-CDT group and UK-CDT group(χ2=1.893, P>0.05). No severe complications were found in all groups. The incidence rates of mild complication of the rt-PA-CDT group, UK-CDT group and anticoagulation group were 16.3%(7/43), 17.9%(7/39)and 8.8%(3/34), respectively, and there were no significant differences among the three groups(χ2=1.396, P>0.05). Conclusion The clinical efficacy of CDT using rt-PA and UK for subacute DVT is better than simple anticoagulation treatment.Thrombolytic rate of rt-PA is superior to UK.

Trombólisis con activador recombinante del plasminógeno tisular (rt-PA) para el ataque cerebro vascular agudo: la experiencia colombiana / Thrombolysis with rt-PA for acute stroke: Colombian experience

RESUMEN El tratamiento con activador recombinante del plasminógeno tisular (sigla en inglés rt-PA), aplicado por vía intravenosa (VIV) es el procedimiento de primera línea en casos de ataque cerebrovascular agudo (ACVA) en una ventana de 4,5 horas. En Colombia hay una experiencia publicada del uso exitoso de este medicamento. En el número actual se publica una nueva experiencia del uso de rt-PA en el caribe colombiano, de gran utilidad para reseñar los artículos publicados en Colombia acerca del tema.

ABSTRACT Treatment with intravenous recombinant tissue plasminogen activator (rt-PA) for acute stroke (AS) is the first line procedure for patients in 4,5 hours window. In Colombia there is a published experience about the successful use of this medication. In the currently issue a new experience from Colombian Caribbean is presented, which it is taken in advantage for briefly reviewing the published papers about the theme in our country.

Clinical study on Ginkgo biloba lactone injection combined with rt-PA intravenous thrombolysis in treatment of acute ischemic stroke / 药物评价研究

Objective To explore the safety and clinical efficacy of Ginkgo biloba lactone injection combined with Alteplase intravenous thrombolysis in treatment of acute ischemic stroke.Methods Totally 87 patients were recruited and divided into control group and test group.The,patients in control group (39 cases) were given Alteplase 0.9 mg/kg for injection,intravenous bolus total dose 10％ was given within 1 min,then intravenous infusion of the remaining 90％ was given in 1 h,and given basic therapy after 24 h.The 48 cases in test group,which were immediately iv Ginkgo biloba lactone injection after intravenous thrombolysis,6 mL added into 250 mL saline,once daily for 14 d,and also were given basic therapy after 24 h.All NIHSS scores were recorded before treatment,14 d and 90 d after treatment,and the adverse events were recorded.The modified Rankin scale (mRS) score and BI index were performed at 14 and 90 d after admission.Patients in two groups were classified according to the TOAST classification,and the patients with large-arteryatherosclerosis and small-artery occlusion were analyzed.Results No intracranial hemorrhage occurred in the two groups.The NIHSS score and mRS score of test group were significantly lower than that of control group,and BI index was significantly increased 90 d after treatment.The NIHSS score and mRS score of test group were significantly lower than that of control group,and BI index was significantly increased90 d after treatment of patients with large-artery atherosclerosis.But there was no significant difference between test group and control group of patients with small-artery occlusion.Conclusion Ginkgo biloba lactone injection combined with rt-PA intravenous thrombolysis in the treatment of acute ischemic stroke has high safety,and can improve the prognosis of patients.

Application of 99TCm tracer technique in rabbit cerebral thromboembolic stroke / 药物评价研究

Objective To study the application of 99Tcm in rabbit cerebral thromboembolic stroke and thrombolysis effect of recombinant tissue plasminogen activator (rt-PA).Methods The 0.5 mL radioactive pertechnetate sodium (specification:5 mCi/2mL and radiation intensity 92.5 MBq/mL) was combined with 30 μL stannous chloride (5 mg/mL),and the 20 μL mixture was joined to whole blood,red blood cells,and plasma for labelling.Then 50 μL CaCl2 (0.5 mol/L) and bovine thrombin (50 IU/mL) were doped in mixture,and rapidly sucked into a polyethylene plastic pipe (PE80).Thrombus was formed for 2 h at 37 ℃ and cut into small pieces of 10 mm.Autologous blood clots combined with 99Tcm from external carotid artery were injected to internal carotid artery of rabbit,the radioactivity (counts per minute,CPM) was measured by gamma counting instrument,and the improvement of rt-PA 4.5 mg/kg (clinical equivalent dose) on this model was observed.Results After thromboembolism,CPM increased approximately by (5.1 ± 1.3) times,which suggested that the model was reliable.The rt-PA 4.5 mg/kg had significant progressive thrombolysis effect.Conclusion 99Tcm tracer technology could be applied to rabbit cerebral stroke model,which is stable and reliable

Effect of early intravenous thrombolysis with an alteplase on the patients with acute cerebral infarction / 中国生化药物杂志

Objective To investigate the clinical effect of of rt-Pa Early Thrombolytic Therapy on the Patients with Acute Cerebral Infarction (ACI). Methods 40 patients with acute cerebral infarction were randomly divided into rt-PA group and control group, 20 cases in each group. The treatment time window was less than 3 hours. On the basis of the routine medication of cerebral infarction, rt-PA group was given rt-PA intravenous thrombolytic therapy, the control group was treated with sodium ozagrel. The National Institutes of Health Stroke Scale (NIHSS) and Barthel index (BI) were used to evaluate the efficacy and safety. Results The NIHSS scores of two groups after treatment were significantly improved compared with before treatment, rt-PA group improved significantly better than the control group (P<0.05); At 21 days of treatment, the excellence rate of rt-PA group was 80% and the ratio of BI≥95 was 40.00%, the excellence rate of control group was 25.0% and the ratio of BI≥95 was 20.00%, the rt-PA group was significantly higher than the control Group (P<0.01); there was no significant difference between the two groups in the mortality rate, the incidence of secondary cerebral hemorrhage and vascular restenosis in the two groups. Conclusion Within 3 hours of onset of ACI, compared with the sodium ozagrel therapy, the rt-PA intravenous thrombolytic therapy is more safe and effective in the treatment of ACI patients, and it is worthy to be widely used in clinical treatment.

Efficacy and safety of intravenous thrombolysis in hyperglycemic patients with minor stroke / 实用医学杂志

Objective To assess the efficacy and safety of thrombolysis therapy for hyperglycemic patients suffering from minor stroke. Methods Intravenous thrombolysis by rtPA was given to hyperglycemic patients suffering from minor stroke. The recovery of neurological deficits and other clinical parameters were recorded 24 hours ,7 days and 90 days after treatment in randomized thrombolytic group and non-thrombolytic group. Results Neurological recovery rate of minor stroke patients with diabetes in thrombolytic group was higher than that in non-thrombolytic group 24 hours,7 days and 90 days after the treatment(P < 0.05)and the incidence of aggravation or worsening of clinical symptoms in thrombolytic group was lower than that of non-thrombolytic group(P < 0.05). There was no significant difference in the recovery rate of neurological deficits and the incidence of exacerbation or deterioration of clinical symptoms in hyperglycemic patients suffering from minor stroke. No intra-cranial hemorrhage occurred in both groups. Conclusion It is of great significance for minor stroke patients with diabetes to receive intravenous thrombolysis ,which is a safer clinical alternative.

Effect of early intravenous thrombolysis with an alteplase on the patients with acute cerebral infarction / 中国生化药物杂志

Objective To investigate the clinical effect of of rt-Pa Early Thrombolytic Therapy on the Patients with Acute Cerebral Infarction (ACI). Methods 40 patients with acute cerebral infarction were randomly divided into rt-PA group and control group, 20 cases in each group. The treatment time window was less than 3 hours. On the basis of the routine medication of cerebral infarction, rt-PA group was given rt-PA intravenous thrombolytic therapy, the control group was treated with sodium ozagrel. The National Institutes of Health Stroke Scale (NIHSS) and Barthel index (BI) were used to evaluate the efficacy and safety. Results The NIHSS scores of two groups after treatment were significantly improved compared with before treatment, rt-PA group improved significantly better than the control group (P<0.05); At 21 days of treatment, the excellence rate of rt-PA group was 80% and the ratio of BI≥95 was 40.00%, the excellence rate of control group was 25.0% and the ratio of BI≥95 was 20.00%, the rt-PA group was significantly higher than the control Group (P<0.01); there was no significant difference between the two groups in the mortality rate, the incidence of secondary cerebral hemorrhage and vascular restenosis in the two groups. Conclusion Within 3 hours of onset of ACI, compared with the sodium ozagrel therapy, the rt-PA intravenous thrombolytic therapy is more safe and effective in the treatment of ACI patients, and it is worthy to be widely used in clinical treatment.

Efficacy and safety of intravenous thrombolysis in hyperglycemic patients with minor stroke / 实用医学杂志

Objective To assess the efficacy and safety of thrombolysis therapy for hyperglycemic patients suffering from minor stroke. Methods Intravenous thrombolysis by rtPA was given to hyperglycemic patients suffering from minor stroke. The recovery of neurological deficits and other clinical parameters were recorded 24 hours ,7 days and 90 days after treatment in randomized thrombolytic group and non-thrombolytic group. Results Neurological recovery rate of minor stroke patients with diabetes in thrombolytic group was higher than that in non-thrombolytic group 24 hours,7 days and 90 days after the treatment(P < 0.05)and the incidence of aggravation or worsening of clinical symptoms in thrombolytic group was lower than that of non-thrombolytic group(P < 0.05). There was no significant difference in the recovery rate of neurological deficits and the incidence of exacerbation or deterioration of clinical symptoms in hyperglycemic patients suffering from minor stroke. No intra-cranial hemorrhage occurred in both groups. Conclusion It is of great significance for minor stroke patients with diabetes to receive intravenous thrombolysis ,which is a safer clinical alternative.

Efficacy and safety of intravenous thrombolysis with different doses of rt-PA in the treatment of acute anterior circulation cerebral infarction with atrial fibrillation / 中国生化药物杂志

Objective To explore the Efficacy and safety of intravenous thrombolysis with different doses of rt-PA in the treatment of acute anterior circulation cerebral infarction with atrial fibrillation.Methods Retrospective analysis of 61 cases of patients with anterior circulation of cerebral infarction with atrial fibrillation from October 2009 to October 2014 in the First Affiliated Hospital of Xiamen University, the incidence within 4.5 hours of intravenous thrombolysis,and divided into two groups by rt-PA usage,19 cases in adequate group,received 0.9 mg/kg rt-PA intravenous thrombolytic therapy,42 cases in low dose group, received 0.6 mg/kg rt-PA intravenous thrombolysis.Before and after thrombolysis 1,7 and 30 days,NIHSS score was measured, the indexes of coagulation were observed at before thrombolysis and 1,7 days after thrombolysis,,CT scans were performed at 1, 7, and 14 days after thrombolysis,and Rankin (MRS) scores were compared at 90 days after thrombolysis.Results NIHSS 1,7,30 days scores of 2 groups were significantly decreased after thrombolysis(P<0.05),there was no statistically significant at at each time point after thrombolysis.Plasma prothrombin time increased significantly at 1 day and 7 days after thrombolysis,fibrinogen was significantly lower,compared with the low dose group, the difference was significant (P<0.05).There was no significant difference between the two groups in clinical outcome and mortality.The rate of mucosal bleeding in low dose group was lower than that in adequate group (P<0.05).Conclusion Low-dose rt-PA group intravenous thrombolysis with anterior circulation of atrial fibrillation is more safe,can reduce the risk of bleeding, reduce neurological deficits and improve the quality of life of patients.

Prognosis Effect of Shengmai Injection to the rt-PA Thrombolysis on Broadened Therapeutic Window Pa-tients of Mild-to-moderate Cerebral Infarction / 中国药房

OBJECTIVE:To explore the prognosis effect of Shengmai injection to the rt-PA thrombolysis on broadened thera-peutic window patients of mild-to-moderate cerebral infarction under the guidance of computer tomography(CT). METHODS:168 patients with mild-to-moderate cerebral infarction were randomly divided into control group (84 cases) and observation group (84 cases). Control group received rt-PA(0.9 mg/kg),and 10% of the total rt-PA was mixed and injected into patients within 1 min, the rest 90% adding into 250 ml 0.9% Sodium chloride injection (no less than 1 h),CT was performed after 24 h thrombolytic therapy,and the patients with no intracerebral hemorrhage in re-examination received 300 mg/d aspirin for 10 d,then 100 mg/d for 90 d,and appropriate statins,calcium antagonists,β-blockers and nitrates;observation group additionally received 40 ml Sheng-mai injection,adding into 250 ml 5% Glucose injection,intravenous infusion,once a day,for 28 d. National Institutes of Health Stroke Scale (NIHSS) score,Rankin score,daily living-Barthel Index (Barthel) score,rate of symptomatic intracranial hemor-rhage,rate of secondary hemorrhage,hospitalization time,3-month postoperative mortality and incidence of adverse reactions in 2 groups were observed. RESULTS:Before treatment,there were no significant differences in the NIHSS score,Rankin score and Barthel score(P>0.05). The NIHSS score in 2 groups after 6 h,24 h and 7 d were significantly lower than before,and observa-tion group was lower than control group after 24 h and 7 d;Rankin score after 3 months was significantly lower than before,and observation group was lower than control group;Barthel score after 3 months was significantly higher than before,and observation group was higher than control group,The differences were statistically significant (P<0.05). The hospitalization time in observa-tion group was significantly shorter than in control group,and 3-month postoperative mortality was significantly lower than control group,the differences were statistically significant(P<0.05). There were no obvious adverse reactions during treatment. CONCLU-SIONS:Based on conventional treatment,Shengmai injection has improvement in the rt-PA intravenous thrombolysis on broadened therapeutic window patients of mild-to-moderate cerebral infarction under the guidance of CT,it can reduce NIHSS score and Rankin score,increase Barthel score,shorten hospitalization time and reduce the 3-month postoperative mortality,with good safety.